claforan powder and solvent for solution for injection
zentiva saglik urunleri san.ve tic. a.s. - cefotaxime (cefotaxime sodium) - powder and solvent for solution for injection - 1000mg
sedol - etoposide concentrate for solution for infusion 20 mgml
unimed sdn bhd - etoposide -
synercid powder for solution
monarch pharmaceuticals ireland limited - quinupristin; dalfopristin - powder for solution - 150mg; 350mg - quinupristin 150mg; dalfopristin 350mg - streptogramins
condylox podofilox solution
actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml
condylox podofilox gel
actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g
condylox- podofilox gel
allergan, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g - condylox gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). this product is not indicated in the treatment of mucous membrane warts (see precautions ). although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma and "bowenoid papulosis" is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 0.5%. condylox gel 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any components of the formulation.
palonosetron hexal 250 mikrogramm
palonosetron stada 250 µg/5 ml injektionslösung
ioflupan (123i) rotop 74 mbq/ml injektionslösung
secretin iberoinvesa pharma, 100 klinische einheiten (cu), pulver und lösungsmittel zur herstellung einer injektions- bzw. infusionslösung